- Home
- TKLF vs ATHA Comparison
TKLF vs ATHA Comparison
Compare TKLF & ATHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKLF
- ATHA
- Stock Information
- Founded
- TKLF 2006
- ATHA 2011
- Country
- TKLF Japan
- ATHA United States
- Employees
- TKLF N/A
- ATHA N/A
- Industry
- TKLF Other Specialty Stores
- ATHA Medicinal Chemicals and Botanical Products
- Sector
- TKLF Consumer Discretionary
- ATHA Health Care
- Exchange
- TKLF Nasdaq
- ATHA Nasdaq
- Market Cap
- TKLF 15.7M
- ATHA 14.8M
- IPO Year
- TKLF 2022
- ATHA 2020
- Fundamental
- Price
- TKLF $3.90
- ATHA $0.38
- Analyst Decision
- TKLF
- ATHA Buy
- Analyst Count
- TKLF 0
- ATHA 4
- Target Price
- TKLF N/A
- ATHA $11.25
- AVG Volume (30 Days)
- TKLF 4.7K
- ATHA 191.8K
- Earning Date
- TKLF 07-10-2025
- ATHA 08-07-2025
- Dividend Yield
- TKLF N/A
- ATHA N/A
- EPS Growth
- TKLF N/A
- ATHA N/A
- EPS
- TKLF 1.57
- ATHA N/A
- Revenue
- TKLF $210,119,238.00
- ATHA N/A
- Revenue This Year
- TKLF N/A
- ATHA N/A
- Revenue Next Year
- TKLF N/A
- ATHA N/A
- P/E Ratio
- TKLF $2.36
- ATHA N/A
- Revenue Growth
- TKLF 7.38
- ATHA N/A
- 52 Week Low
- TKLF $2.20
- ATHA $0.22
- 52 Week High
- TKLF $7.28
- ATHA $3.67
- Technical
- Relative Strength Index (RSI)
- TKLF 52.05
- ATHA 49.40
- Support Level
- TKLF $3.28
- ATHA $0.36
- Resistance Level
- TKLF $3.94
- ATHA $0.40
- Average True Range (ATR)
- TKLF 0.19
- ATHA 0.04
- MACD
- TKLF -0.01
- ATHA -0.01
- Stochastic Oscillator
- TKLF 83.43
- ATHA 30.60
About TKLF Yoshitsu Co. Ltd
Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores, Online Stores and Services, and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from Hong Kong, followed by Japan, the United States, and other overseas markets.
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.